



Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)

David S. Goldfarb¹ · John C. Lieske² · Jaap Groothoff³ · Gesa Schalk⁴ · Kerry Russell⁵ · Shuli Yu⁵ · Blaz Vrhnjak⁶

Published online: 5 June 2023
© The Author(s) 2023

Correction to: Urolithiasis (2023) 51:80
<https://doi.org/10.1007/s00240-023-01453-3>

The original version of this article unfortunately contained a mistake. The copyright holder for this article was incorrectly given as

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply

but should have been

© The Author(s) 2023

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00240-023-01453-3>.

✉ David S. Goldfarb
David.Goldfarb@nyulangone.org

¹ New York Harbor Department of Veterans Affairs Medical Center, New York University School of Medicine, New York, NY, USA

² Mayo Clinic, Rochester, MN, USA

³ Academic Medical Center (AMC), Amsterdam, The Netherlands

⁴ Kindernierenzentrum, Bonn, Germany

⁵ Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company, Lexington, MA, USA

⁶ Novo Nordisk, Søborg, Denmark